
Maharashtra FDA Withdraws Cipla Drug Licence Cancellation After Bombay HC Rebuke
The story in brief
The Bombay High Court ruled the Maharashtra FDA's procedure violated natural justice principles after it cancelled Cipla's drug licence over alleged compliance issues with Reactin Plus Tablets. The regulator withdrew the cancellation order and issued a fresh show-cause notice following the court's intervention, which questioned the fairness of holding the company on a public holiday without adjournment.